Abiopharma

🔍 BAKER BROS. ADVISORS LP (Executive)

Company: MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Report Date: 2025-08-18

Detailed Transactions and Holdings:

• Acquired 2,460 shares of Common Stock at $372.8693 per share (Direct)
  Date: 2025-08-18 | Code: P | equity_swap_involved: false | shares_owned_after: 197,085.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 26,704 shares of Common Stock at $372.8693 per share (Direct)
  Date: 2025-08-18 | Code: P | equity_swap_involved: false | shares_owned_after: 1,885,795.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Acquired 675 shares of Common Stock at $374.4338 per share (Direct)
  Date: 2025-08-18 | Code: P | equity_swap_involved: false | shares_owned_after: 197,760.00 | transaction_form_type: 4 | Footnotes: F15, F2
• Acquired 7,325 shares of Common Stock at $374.4338 per share (Direct)
  Date: 2025-08-18 | Code: P | equity_swap_involved: false | shares_owned_after: 1,893,120.00 | transaction_form_type: 4 | Footnotes: F15, F3
• Acquired 480 shares of Common Stock at $380.4365 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 198,240.00 | transaction_form_type: 4 | Footnotes: F9, F2
• Acquired 5,209 shares of Common Stock at $380.4365 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,898,329.00 | transaction_form_type: 4 | Footnotes: F9, F3
• Acquired 176 shares of Common Stock at $380.78 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 198,416.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,919 shares of Common Stock at $380.78 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,900,248.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 873 shares of Common Stock at $381.1216 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 199,289.00 | transaction_form_type: 4 | Footnotes: F10, F2
• Acquired 9,477 shares of Common Stock at $381.1216 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,909,725.00 | transaction_form_type: 4 | Footnotes: F10, F3
• Acquired 105 shares of Common Stock at $382.2891 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 199,394.00 | transaction_form_type: 4 | Footnotes: F11, F2
• Acquired 1,136 shares of Common Stock at $382.2891 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,910,861.00 | transaction_form_type: 4 | Footnotes: F11, F3
• Acquired 262 shares of Common Stock at $382.8213 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 199,656.00 | transaction_form_type: 4 | Footnotes: F12, F2
• Acquired 2,838 shares of Common Stock at $382.8213 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,913,699.00 | transaction_form_type: 4 | Footnotes: F12, F3
• Acquired 373 shares of Common Stock at $383.7872 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 200,029.00 | transaction_form_type: 4 | Footnotes: F13, F2
• Acquired 4,049 shares of Common Stock at $383.7872 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,917,748.00 | transaction_form_type: 4 | Footnotes: F13, F3
• Acquired 1,248 shares of Common Stock at $385.0573 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 201,277.00 | transaction_form_type: 4 | Footnotes: F14, F2
• Acquired 13,545 shares of Common Stock at $385.0573 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,931,293.00 | transaction_form_type: 4 | Footnotes: F14, F3
• Acquired 409 shares of Common Stock at $387.068 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 201,686.00 | transaction_form_type: 4 | Footnotes: F16, F2
• Acquired 4,441 shares of Common Stock at $387.068 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,935,734.00 | transaction_form_type: 4 | Footnotes: F16, F3
• Acquired 34 shares of Common Stock at $389.0 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 201,720.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 366 shares of Common Stock at $389.0 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,936,100.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 231 shares of Common Stock at $389.8878 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 201,951.00 | transaction_form_type: 4 | Footnotes: F17, F2
• Acquired 2,506 shares of Common Stock at $389.8878 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,938,606.00 | transaction_form_type: 4 | Footnotes: F17, F3
• Acquired 862 shares of Common Stock at $392.2429 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 202,813.00 | transaction_form_type: 4 | Footnotes: F18, F2
• Acquired 9,362 shares of Common Stock at $392.2429 per share (Direct)
  Date: 2025-08-20 | Code: P | equity_swap_involved: false | shares_owned_after: 1,947,968.00 | transaction_form_type: 4 | Footnotes: F18, F3

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Madrigal Pharmaceuticals, Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $372.59 to $373.54, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F2: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.
• F3: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. Baker Bros. Advisors (GP) LLC (the "Adviser GP") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.
• F4: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.
• F5: Includes beneficial ownership of 3,825 shares of Common Stock received from vested restricted stock units of the Issuer (each an "RSU") each previously granted to Julian C. Baker and Dr. Raymond Cheong in their capacity as directors of the Issuer.
• F6: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the non-qualified stock options exercisable solely into Common Stock ("Stock Options"), RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.
• F7: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the Stock Options and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such service on the board of directors of the Issuer.
• F8: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.
• F9: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $380.03 to $380.84, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F10: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $380.98 to $381.94, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F11: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $382.00 to $382.36, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F12: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $382.20 to $383.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F13: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $383.42 to $384.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F14: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $385.00 to $385.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F15: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $374.09 to $374.67, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F16: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $387.00 to $387.17, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F17: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $389.44 to $390.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
• F18: The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $391.69 to $392.57, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.